5-Amino-1MQ
Small-molecule NNMT inhibitor (5-amino-1-methylquinolinium); not a peptide; three PubMed-indexed papers, animal and cell studies only.
60-Second Scientific Briefing
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small molecule, not a peptide, that inhibits the enzyme nicotinamide N-methyltransferase (NNMT). Only three PubMed-indexed papers exist, all in experimental animals or cells; in diet-induced obese animals, the inhibitor combined with a low-fat diet reduced fat and body weight. Not approved by the US FDA or any other regulator; it is a research compound.
What is 5-Amino-1MQ?
Pharmacological Classification & Molecular Identity5-Amino-1MQ (5-amino-1-methylquinolinium) is a small molecule, not a peptide, that inhibits the enzyme nicotinamide N-methyltransferase (NNMT). [1] Sci Rep, 2022 ↗
Verified Chemical & Regulatory Registry Identifiers
Mechanism of Action & Receptor Targets
Biological Pathway and Target BindingReceptor Selectivity: NNMT is a metabolic enzyme active in fat tissue and some tumours; blocking it is studied for effects on fat metabolism and cell growth. [1] Sci Rep, 2022 ↗
Regulatory & FDA Approval Status
Legal and Regulatory ClassificationsNot approved by the US FDA or any other regulator; it is a research compound. [1] Sci Rep, 2022 ↗
5-Amino-1MQ is not approved for commercial sale, prescription therapy, or compounded medication distribution. It exists strictly within authorized scientific and clinical research frameworks.
Human Evidence & Clinical Trials
Clinical Study Readouts and Evidence SynthesesNo human clinical trial has been published. Sci Rep 2022: in diet-induced obese animals, the NNMT inhibitor combined with a low-fat diet normalised adiposity and body weight faster than the diet switch alone, and the study examined gut-microbiome changes. J Obstet Gynaecol 2021: the compound reduced proliferation of HeLa cervical cancer cells in the laboratory. [1] Sci Rep, 2022 ↗ [2] J Obstet Gynaecol, 2021 ↗
Clinical Evidence
No human clinical trial has been published. Sci Rep 2022: in diet-induced obese animals, the NNMT inhibitor combined with a low-fat diet normalised adiposity and body weight faster than the diet switch alone, and the study examined gut-microbiome changes. J Obstet Gynaecol 2021: the compound reduced proliferation of HeLa cervical cancer cells in the laboratory.
Safety Profile & Clinical Limitations
Documented Adverse Events and Known UncertaintiesThere are no human safety data. [1] Sci Rep, 2022 ↗
Effects and safety in people, oral availability and the quality of non-pharmaceutical material are unknown. [1] Sci Rep, 2022 ↗
Dose Approval Status
Commercial Dosing Status and Policy DirectivesNo dose is approved or established for humans, and no human dose-finding study has been published. [1] J Obstet Gynaecol, 2021 ↗
Under Egypt Peptides medical governance policies, no personal dosages, titration intervals, cycles, stacking recommendations, or self-injection instructions may be provided for unapproved investigational compounds. Clinical study protocols represent controlled experimental research parameters exclusively.
What is Known vs. What is Unknown
Evidence Comparison and Clinical Evidence Boundaries✓ Confirmed Scientific Evidence
- 5-Amino-1MQ (5-amino-1-methylquinolinium) is a small molecule, not a peptide, that inhibits the enzyme nicotinamide N-methyltransferase (NNMT).
- Targets & Selectivity: NNMT is a metabolic enzyme active in fat tissue and some tumours; blocking it is studied for effects on fat metabolism and cell growth.
- No human clinical trial has been published. Sci Rep 2022: in diet-induced obese animals, the NNMT inhibitor combined with a low-fat diet normalised adiposity and body weight faster than the diet switch alone, and the study examined gut-microbiome changes. J Obstet Gynaecol 2021: the compound reduced proliferation of HeLa cervical cancer cells in the laboratory.
- Safety considerations: There are no human safety data.
? Unknown / Under Ongoing Investigation
- Effects and safety in people, oral availability and the quality of non-pharmaceutical material are unknown.
Verified Questions & Answers
10 Verified scientific answers with permanent anchor keys5-Amino-1MQ (5-amino-1-methylquinolinium) is a small molecule, not a peptide, that inhibits the enzyme nicotinamide N-methyltransferase (NNMT).
NNMT is a metabolic enzyme active in fat tissue and some tumours; blocking it is studied for effects on fat metabolism and cell growth.
No. Not approved by the US FDA or any other regulator; it is a research compound.
No human clinical trial has been published. Only three PubMed-indexed papers exist, all in experimental animals or cells; in diet-induced obese animals, the inhibitor combined with a low-fat diet reduced fat and body weight.
No human clinical trial has been published. Sci Rep 2022: in diet-induced obese animals, the NNMT inhibitor combined with a low-fat diet normalised adiposity and body weight faster than the diet switch alone, and the study examined gut-microbiome changes. J Obstet Gynaecol 2021: the compound reduced proliferation of HeLa cervical cancer cells in the laboratory.
- Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice (Sci Rep, 2022-01-10)
- Small molecule inhibitor of nicotinamide N-methyltransferase shows anti-proliferative activity in HeLa cells (J Obstet Gynaecol, 2021-03-01)
There are no human safety data.
Effects and safety in people, oral availability and the quality of non-pharmaceutical material are unknown.
No dose is approved or established for humans, and no human dose-finding study has been published.
- Small molecule inhibitor of nicotinamide N-methyltransferase shows anti-proliferative activity in HeLa cells (J Obstet Gynaecol, 2021-03-01)
There is no approved product label, so no official storage instructions exist.
It is not named individually on the 2026 WADA Prohibited List. Under section S0 (non-approved substances), any pharmacological substance without a current approval by a government health authority for human therapeutic use is prohibited at all times. Athletes should confirm with their national anti-doping organisation.
- WADA Prohibited List (World Anti-Doping Agency)
Egypt Peptides publishes reviewed scientific reference monographs for documentation and research. The site does not give individual medical advice, preparation or injection instructions, combination protocols or off-label use instructions. Decisions about any medicine belong to the treating physician.
Authoritative Sources & Literature Registry
Regulatory dossiers, clinical trial registries, and published studiesReduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice ↗
https://pubmed.ncbi.nlm.nih.gov/35013352/
Small molecule inhibitor of nicotinamide N-methyltransferase shows anti-proliferative activity in HeLa cells ↗
https://pubmed.ncbi.nlm.nih.gov/33645410/